The Glaucoma Device Market Turns a Corner

article image

Much room for improvement exists in the treatment of glaucoma. Between eye drops and major surgery with unpredictable outcomes, there has been a vast treatment gulf, now beginning to be filled by companies offering less invasive device treatments. Glaucoma presents a challenging device target; many companies have raised as much as $100 million, without a product on the market to show for it. But finally, the field of micro invasive glaucoma surgery has seen its first real successes.

Place Summary Here A year ago, the CEO of an early-stage glaucoma start-up was at Glaucoma 360, a meeting sponsored by the Glaucoma Research Foundation.

Place Article Here He was attending a panel of strategic investors in which it was discussed that there was much M&A and investment activity going on in ophthalmology in general, but for glaucoma companies, not so much. That had been his own experience, in hunting for funding for his company. A year later, things have turned around—maybe not 360 degrees—but a great deal. This company founder is pleased to say that while it had previously been tough to gain traction with investors, now they are calling him.  


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: